Compare
Biolife Solutions Inc vs Vaso Corp vs Ceribell, Inc. vs Outset Medical, Inc.
| Latest fiscal year | Biolife Solutions Inc BLFS | Vaso Corp VASO | Ceribell, Inc. CBLL | Outset Medical, Inc. OM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $96.21M | $89.10M | $89.06M | $119.48M |
| Revenue growth (YoY) | +28.9% | +2.7% | +36.1% | +5.1% |
| Gross margin | 64.6% | 61.4% | 87.9% | 39.1% |
| Operating margin | -17.3% | -3.2% | -65.6% | -55.8% |
| Net margin | -4.8% | 1.8% | -60.0% | -68.3% |
| Net income | -$4.59M | $1.57M | -$53.41M | -$81.65M |
| EPS (Diluted) | -$0.10 | $0.01 | -$1.46 | -$5.37 |
| Operating cash flow | $20.11M | $9.27M | -$40.81M | -$46.33M |
| Free cash flow | $10.64M | n/a | -$41.58M | -$47.12M |
| Cash & equivalents | $33.04M | $35.05M | $40.48M | $35.01M |
| Total assets | $405.88M | $88.35M | $195.80M | $264.50M |
| Total liabilities | $34.00M | n/a | $40.47M | $137.54M |
| Shareholders' equity | $371.89M | $29.43M | $155.34M | $126.95M |
| Return on year-end equity | -1.2% | 5.3% | -34.4% | -64.3% |
| Shares outstanding | 48.20M | 175.95M | 37.49M | 18.17M |
Revenue, most recent five fiscal years
| Fiscal year | Biolife Solutions Inc | Vaso Corp | Ceribell, Inc. | Outset Medical, Inc. |
|---|---|---|---|---|
| Latest | $96.21M Ended 2025-12-31 | $89.10M Ended 2025-12-31 | $89.06M Ended 2025-12-31 | $119.48M Ended 2025-12-31 |
| 1 year earlier | $74.65M Ended 2024-12-31 | $86.77M Ended 2024-12-31 | $65.44M Ended 2024-12-31 | $113.69M Ended 2024-12-31 |
| 2 years earlier | $68.02M Ended 2023-12-31 | $81.02M Ended 2023-12-31 | $45.23M Ended 2023-12-31 | $130.38M Ended 2023-12-31 |
| 3 years earlier | $76.24M Ended 2022-12-31 | $79.29M Ended 2022-12-31 | n/a | $115.38M Ended 2022-12-31 |
| 4 years earlier | $119.16M Ended 2021-12-31 | $75.58M Ended 2021-12-31 | n/a | $102.60M Ended 2021-12-31 |